Glycophos

Glycophos, containing sodium glycerophosphate pentahydrate, is a sterile aqueous solution for injection intended for intravenous administration. It is supplied as a prescription‑only product in the European market and provides phosphate ions to support metabolic processes. The formulation is used in clinical settings to correct low serum phosphate levels and to supplement parenteral nutrition regimens. Its composition and route of delivery allow rapid correction of phosphate deficits.

Glycophos is indicated for conditions where phosphate replenishment is required, particularly in hospitalized patients receiving intravenous therapy.

- Treatment of hypophosphatemia associated with acute or chronic illnesses. - Phosphate replacement in total parenteral nutrition (TPN) formulations. - Support of patients undergoing renal replacement therapy who develop phosphate loss. - Management of phosphate depletion during prolonged fasting or severe malnutrition. - Adjunctive therapy in critical care settings to maintain electrolyte balance. - Correction of phosphate deficits prior to major surgical procedures.

Phosphate infusion may be associated with a range of adverse effects, most of which are related to the rate of administration and patient-specific factors.

Common: - Mild nausea or vomiting. - Transient flushing or warmth at the infusion site. - Temporary elevation of serum calcium levels. - Mild headache or dizziness. - Slight increase in serum potassium. - Local irritation or pain at the injection site.

Serious: - Severe hyperphosphatemia leading to calcium‑phosphate precipitation. - Acute respiratory distress due to pulmonary edema. - Cardiac arrhythmias associated with electrolyte imbalance. - Hypotension from rapid infusion. - Allergic reactions such as urticaria or anaphylaxis. - Renal failure exacerbation due to phosphate overload. - Metabolic acidosis in susceptible patients.

When prescribing Glycophos, clinicians should evaluate patient history and laboratory values to minimize the risk of complications.

- Verify baseline serum phosphate, calcium, and renal function before initiation. - Adjust infusion rate to avoid rapid shifts in phosphate concentration. - Use caution in patients with severe renal impairment or on dialysis. - Monitor electrolytes regularly during therapy, especially calcium and magnesium. - Avoid concurrent administration with calcium‑containing solutions in the same line. - Consider dose reduction in patients with a history of hyperphosphatemia. - Discontinue if signs of hypersensitivity or severe electrolyte disturbances develop.

Glycophos may interact with other intravenous agents or medications that affect electrolyte balance.

Avoid: - Simultaneous infusion with calcium gluconate or calcium chloride in the same line. - Co‑administration with high‑dose vitamin D analogues that increase calcium absorption. - Use with loop diuretics that promote calcium loss without monitoring.

Use with caution: - Concurrent use of bisphosphonates, which can alter phosphate metabolism. - Administration alongside antacids containing aluminum or magnesium. - Patients receiving insulin therapy, as insulin can shift phosphate intracellularly. - Combination with other phosphate binders, requiring careful monitoring of serum levels.